A groundbreaking development in the treatment of advanced prostate cancer

According to the results of a study presented at a meeting held recently by the American Society of Clinical Oncology (ASCO), it was determined that in metastatic prostate cancer (spread to distant tissues), the chemotherapy drug docetaxel, normally used after resistance to hormone suppression therapy develops, produces better results and significantly improves survival when used together with hormone suppression therapy.
What is prostate cancer?
Prostate cancer is the most common type of cancer in men after skin cancer. It ranks second among cancer-related deaths. In addition, prostate cancer is one of the cancer types about which the most remains unknown. More progress is needed in prevention and early diagnosis as well as treatment in order to overcome this cancer. Therefore, research on prostate cancer continues very intensively, and new and promising developments are being recorded every day.
Treatment of prostate cancer
The treatment of prostate cancer, as with other types of cancer, varies according to its stage. While early-stage cancer confined to the prostate and not spread to distant tissues can be readily treated with methods such as surgery, radiotherapy, and active surveillance, curing metastatic cancer—that is, cancer that has extended beyond the prostate and spread to distant tissues—is quite difficult. Therefore, the strategies adopted for patients with advanced prostate cancer that has spread are aimed at prolonging life as much as possible. The standard treatment procedure for these patients is first to prevent the cancer from progressing with androgen deprivation therapy (hormonal therapy), and then, when resistance to this treatment develops, to extend life somewhat further with the chemotherapy drug docetaxel. However, a study presented at the ASCO meeting recently has the potential to change this treatment procedure.
A development in the treatment of metastatic prostate cancer
In the study considered one of the major developments of recent times in metastatic prostate cancer, 790 men 2 with prostate cancer that had spread to distant sites were divided into groups. In one of the groups, docetaxel was administered together with androgen deprivation therapy, while the other group received only androgen deprivation therapy and was followed for 29. When the results were examined, docetaxel given together with androgen deprivation therapy was found to extend survival in the group by approximately 17. It was also observed that, in this group, signs indicating that the disease was progressing (such as rising PSA levels, the appearance of new symptoms, and worsening test results) emerged 6 later. In addition, the method used was found to be more effective particularly in cases with a high tumor burden (tumors that had spread to internal organs and/or at least 4 bones, or had spread to at least one bone outside the pelvic region, and had a Gleason score between 8 and -10). The results obtained are truly striking and have the potential to change standard treatment.
While metastatic prostate cancer was once a complete dead end, this and similar promising studies have begun to open entirely new avenues in the treatment of the disease. Previously, when prostate cancer spread to distant tissues, patients were considered completely without options; now, multiple treatment options are available to prolong life in these patients, and existing options continue to increase with new studies being conducted. A survival advantage of 17 months that may be achieved by administering docetaxel together with androgen deprivation therapy is a result powerful enough to change even the standard treatment currently used for these patients. Nevertheless, more time and research are still needed for this.
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.